Medical-Laser Maker Cynosure Said to Eye Sale Amid Review

Updated on
  • Cynosure said to hold talks with financial advisers on options
  • Sale may draw interest from large, global firms like Allergan

Cynosure Inc., the maker of lasers for medical and cosmetic treatments, is exploring strategic options including a sale, according to people familiar with the matter, amid increasing interest in the technology from larger global companies.

Cynosure is in talks with financial advisers as it weighs strategic options, the people said, asking not to be identified because the deliberations are private. A potential sale of the business, which has a market value of about $1 billion, may attract companies with a presence in aesthetic treatments, such as Botox maker Allergan Plc, as well as other medical-device businesses, the people said.

Shares in Cynosure rose as much as 13 percent Monday, and were trading up 10 percent at 9:39 a.m. in New York.

A representative for Westford, Massachusetts-based Cynosure didn’t respond to messages seeking comment. A spokesman for Allergan declined to comment. No final decision has been made, and the company may choose not to pursue a sale, the people said.

In October, Cynosure Chief Executive Officer Michael Davin said the company was planning to use part of its cash to buy back stock and make acquisitions and that he didn’t pay “a lot of attention to” talk that it could be purchased. Stifel Financial Corp. analysts had suggested both Cynosure and rival Zeltiq Aesthetics Inc. would be attractive to larger health-care companies including Nestle SA’s Galderma or Germany’s Merz Pharma & Co.

Cynosure makes light-based systems used for treatments such as hair and tattoo removal and and scar reduction, according to its website. It holds 37 U.S. patents. The company is scheduled to report fourth-quarter earnings on Feb. 7.

— With assistance by Jared S Hopkins

    Before it's here, it's on the Bloomberg Terminal.